| Website | nereuspharm.com |
| Category | BioTech |
| Phone | 858-587-4090 |
| info@nereuspharm.com | |
| Employees |
| TOTAL | $20M |
| FUNDING TOTAL | $20M |
| Series E, 6/10 HBM BioVentures Alta Partners Forward Ventures Advent International Pacific Venture Capital Roche Venture Fund Astellas Venture Management | $20M |
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
